Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3
- PMID: 16407371
- DOI: 10.1093/hmg/ddi472
Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3
Abstract
Spinocerebellar ataxia type 3 (SCA3), like other polyglutamine (polyQ) diseases, is characterized by the formation of intraneuronal inclusions, but the mechanism underlying their formation is poorly understood. Here, we tested the "toxic fragment hypothesis", which predicts that proteolytic production of polyQ-containing fragments from the full-length disease protein initiates the aggregation process associated with inclusion formation and cellular dysfunction. We demonstrate that the removal of the N-terminus of polyQ-expanded ataxin-3 (AT3) is required for aggregation in vitro and in vivo. Consistently, proteolytic cleavage of full-length, pathogenic AT3 initiates the formation of sodium dodecylsulfate-resistant aggregates in neuroblastoma cells. Although full-length AT3 does not readily aggregate on its own, it is susceptible to co-aggregation with polyQ-expanded AT3 fragments. Interestingly, interaction with soluble polyQ-elongated fragments causes a structural distortion of wild-type AT3 prior to the formation of stable co-aggregates. These results establish the critical role of C-terminal, proteolytic fragments of AT3 in the molecular pathomechanism of SCA3, in strong support of the toxic fragment hypothesis.
Similar articles
-
PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.Neurosci Bull. 2008 Aug;24(4):201-8. doi: 10.1007/s12264-008-0326-9. Neurosci Bull. 2008. PMID: 18668148 Free PMC article.
-
Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.J Biol Chem. 2007 Jun 29;282(26):18851-6. doi: 10.1074/jbc.M611914200. Epub 2007 May 8. J Biol Chem. 2007. PMID: 17488727
-
A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.Neurobiol Dis. 2007 Sep;27(3):362-9. doi: 10.1016/j.nbd.2007.06.005. Epub 2007 Jun 13. Neurobiol Dis. 2007. PMID: 17632007 Free PMC article.
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.Mol Neurobiol. 2014 Jun;49(3):1513-31. doi: 10.1007/s12035-013-8596-2. Epub 2013 Nov 29. Mol Neurobiol. 2014. PMID: 24293103 Free PMC article. Review.
Cited by
-
Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.Nature. 2011 Nov 23;480(7378):543-6. doi: 10.1038/nature10671. Nature. 2011. PMID: 22113611
-
A polymer physics perspective on driving forces and mechanisms for protein aggregation.Arch Biochem Biophys. 2008 Jan 1;469(1):132-41. doi: 10.1016/j.abb.2007.08.033. Epub 2007 Sep 15. Arch Biochem Biophys. 2008. PMID: 17931593 Free PMC article. Review.
-
Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3.Front Mol Neurosci. 2018 Oct 10;11:368. doi: 10.3389/fnmol.2018.00368. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30364204 Free PMC article.
-
Endosome mediated nucleocytoplasmic trafficking and endomembrane allocation is crucial to polyglutamine toxicity.Cell Biol Toxicol. 2024 Jun 20;40(1):48. doi: 10.1007/s10565-024-09891-4. Cell Biol Toxicol. 2024. PMID: 38900277 Free PMC article.
-
Calpain-mediated proteolysis as driver and modulator of polyglutamine toxicity.Front Mol Neurosci. 2022 Oct 19;15:1020104. doi: 10.3389/fnmol.2022.1020104. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36385755 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous